Camp4 Therapeutics is seeking $75 million in its IPO to advance clinical-stage programs. Learn more about CAMP stock and ...

Sandra A. Banta-Wright, MN, RNC, NNP; Robert D. Steiner, MD Neonates with profound and prolonged hyperammonemia with coma due to urea cycle defect will have had a neurological insult to the brain ...

Younger colon cancer patients had higher levels of metabolites associated with the production and metabolism of an amino acid called arginine, and with the urea cycle compared to their older peers.

Jason Butler, an analyst from JMP Securities, has initiated a new Buy rating on Zevra Therapeutics (ZVRA). Jason Butler has given his Buy ...

Medunik USA, member of Duchesnay Pharmaceutical Group (DPG), one of the few anchor companies selected by the Government of ...

The results revealed that young patients exhibited high levels of metabolites related to arginine production, an amino acid, as well as the urea cycle. These metabolic differences could be attributed ...

BioMarin is adding kindling to the R&D fire, striking a match with CAMP4 Therapeutics for rights to select two targets ...

Camp4 Therapeutics Inc., a Cambridge biotech that has already struck deals with Biogen Inc. and Alnylam Pharmaceuticals Inc., ...

Jack Faris interviews PNRI's brilliant scientists to uncover what excites them about genetic research, what inspired their ...

Researchers have identified a novel therapeutic target for Alzheimer’s disease by focusing on astrocytes, non-neuronal brain cells involved in waste removal.

Cash and cash equivalents totaled €61.6 million as of June 30, 2024, excluding the €48.7 million milestone invoiced in June 2024 (received in August 2024) upon first sale of Ipsen's Iqirvo® (elafibran ...